^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tomaralimab (NM-101)

    i
    Other names: NM-101, OPN-305
    Associations

    News

    Trials
    Company:
    Neuramedy
    Drug class:
    TLR2 antagonist
    Related drugs:
    Associations

    News

    Trials
    2ms
    Anti-TLR2 immunotherapy modulates neuron-to-oligodendrocyte propagation of α-synuclein in mouse and human models. (PubMed, Nat Commun)
    In the transgenic mouse model, NM-101 administration rescued the demyelination phenotype. These findings highlight anti-TLR2 immunotherapy as a potential disease-modifying approach for MSA.
    Preclinical • Journal • IO biomarker
    |
    TLR2 (Toll Like Receptor 2)
    |
    tomaralimab (NM-101)
    11ms
    Phase 1 Single Ascending Dose Study (clinicaltrials.gov)
    P1, N=36, Recruiting, Neuramedy Co. Ltd.
    New P1 trial
    |
    tomaralimab (NM-101)